

# U.S. MARKET COMMERCIALIZATION PLAN CHECKLIST

Issues That Life Science Companies Must Consider When Preparing for the American Market





BioPortUSA's comprehensive Commercialization Plan is aimed at successfully bringing your company's product to market while maximizing its adoption, profitability and value creation.

Although it is recognized that your company may have a number of these items planned, in-process, or completed, this initial process is structured and timed to utilize a small subset of a broader plan to minimize spending while providing a timeline, critical deliverables and clarity.

Specifically, this commercialization plan is structured to address key components including current situational assessment, objectives, organizational gaps and competencies underlying those objectives.

It clarifies the economic value proposition and develops a pro forma P&L to assist in fund raising. By leveraging strategic insights and detailed financial projections, this plan ensures choosing an optimal path to commercialization and sustainable growth.



# **COMMERCIALIZATION PLAN OUTLINE**

### **Overview**

- Aspiration
- Disease State
- Market Size & Opportunity
- Competitive Analysis / Target Market Share Lifecycle
- SWOT Analysis / 5-Forces
- Financials Including 5-Year P&L
- Key Milestones

### **Product**

- Product Description
- Regulatory Pathway
- Product Development Schedule and Lifecycle
- Main Parameters of Value and Unique Differentiators
- Economic Value Propositions
- Evidence-Based Medicine (EBM) Supported Benefits
- Buyer Profiles
- Branding

### **Clinical & Regulatory**

- Regulatory Pathway, Timing, and Claims
- Pivotal Trial Description and Timing
- Ergonomics

### **Service & Warranty**

# **Customer Segmentaion**

- Classification
- Segmentation & Value Drivers for Each
- Medical Affairs



## **Pricing**

- Economic Overview
- Region Floor Pricing
- Volumes
- Market Access and Reimbursement

### **Distribution**

- US Sales Force / Channel Structure
- International Distribution
- Incentive Plan
- Sales Training Plan
- HCP Training / MedAffairs

### **Promotion**

- Positioning Development
- Messaging Development
- Creative Development

### **Pre-Launch & Post-Launch Activities**

# **Commercial Projections**

- Revenue Projections as % of Market
- Pro-Forma P&L Projections Based on Specific Funding/Capital Levels
- Commercialization Schedule
- Regulatory Approval & Launch Dates

# **Budgets**

- Global & Regional
- Demonstration Units



# **PHASE 1: ENGAGEMENT PROCESS**

# **Introductory Meeting Agenda**

### 1. Situational Assessment:

### What is the current status of the product realization process?

- Organization
- Proof of concept
- Clinical Trials
- Market Assessment and EVP

### 2. Objective Review

- Short-term
- Interim
- Long-term

### 3. Organization Strengths & Weaknesses

 Clarify competencies and gaps to meeting commercial objectives and maximizing ROI

# **Deliverables**

### 1. Validation of the Market

Assessment and approach for the US market and the World.

### 2. Economic Value Proposition

Pricing, TAM, Share estimates, etc.

#### 3. Pro Forma P&L

3-5 years for directional guidance and fundraising

### 4. High Level Work Breakdown Structure and Timeline



# U.S. MARKET COMMERCIALIZATION PLAN

This commercialization plan outline offers a structured approach to bring your company to market while maximizing success and minimizing required expenditures. Phase 1 sets up a foundation for success and action moving forward.

The Discovery meeting may impact the order and magnitude of specific items. By leveraging the outlined strategies, it creates an ideal future state with with broad market adoption, long-term profitability and maximum value creation.

BioPortUSA offers access to industry experts and a menu of coordinated services all under one roof, addressing each of these business factors. We facilitate thoughtful, strategic and cost-effective guidance to help your company navigate the complex process for U.S. Market entry.

Contact us to get started.

### **United States**

Mark Lesselroth
President & CEO

mark@bioportusa.com +1 315-569-0642